![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 4 of 4. This is the beginning of the thread.
Posted by paul frank on February 25, 1999, at 20:12:04
Some time ago, I recall reading a short article in "Newsweek" about the development of a skin patch to deliver anti-depressant medication. The article indicated that this method would cut the response time from about 4 weeks to about one week.
Does anyone have any info on this ie approximate release date of product, initial studies re overall effectiveness, etc.
Paul Frank
Posted by anonymous on February 26, 1999, at 19:24:22
In reply to Skin Patch for ADs, posted by paul frank on February 25, 1999, at 20:12:04
> Some time ago, I recall reading a short article in "Newsweek" about the development of a skin patch to deliver anti-depressant medication. The article indicated that this method would cut the response time from about 4 weeks to about one week.
>
> Does anyone have any info on this ie approximate release date of product, initial studies re overall effectiveness, etc.
>
>
> Paul Frank
I have heard of this development. The reason it seems to work faster seems to be that it misses the "first pass" through the liver and isn't detoxified by it. It is a hopeful development and there is a lot of research going on in finding ways to deliver drugs in novel ways.
Posted by Chris on February 27, 1999, at 0:22:16
In reply to Skin Patch for ADs, posted by paul frank on February 25, 1999, at 20:12:04
Selegiline (l-deprenyl, Eldepryl), an MAOI approved by the FDA for Parkinson disease, is in phase III clinical trials. According to a NARSAD report it may be up to three years before it is widely available. Somerset Pharmaceuticals is conducting the trials for use in major depression. The NARSAD article quotes Dr. Alexander Bodkin, Director of McLean Hospital's Clinical Psychopharmacology Research Program and sounds quite positive. Recruitment for the trial apparently ended in Jan (>http://www.mhsource.com/advocacy/narsad/newmeds.html). I have been taking selegiline orally for the past five months and have found it helpful for my severe Bipolar II depression. Other ADs, including wellbutrin and Parnate were associated with cycling. The possible lack of dietary restrictions sound almost good to be true. Hope this helps.
>(National Alliance for Research on Schizophrenia & Depression
Posted by Annie on February 27, 1999, at 10:10:37
In reply to Re: Skin Patch for ADs, posted by Chris on February 27, 1999, at 0:22:16
They are still recruiting for trials of the trans-dermal MAOI patch in some areas. Try calling your local teaching hospitals' psych departments if you are interested.
> Selegiline (l-deprenyl, Eldepryl), an MAOI approved by the FDA for Parkinson disease, is in phase III clinical trials. According to a NARSAD report it may be up to three years before it is widely available. Somerset Pharmaceuticals is conducting the trials for use in major depression. The NARSAD article quotes Dr. Alexander Bodkin, Director of McLean Hospital's Clinical Psychopharmacology Research Program and sounds quite positive. Recruitment for the trial apparently ended in Jan (>http://www.mhsource.com/advocacy/narsad/newmeds.html). I have been taking selegiline orally for the past five months and have found it helpful for my severe Bipolar II depression. Other ADs, including wellbutrin and Parnate were associated with cycling. The possible lack of dietary restrictions sound almost good to be true. Hope this helps.
> >(National Alliance for Research on Schizophrenia & Depression
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.